Drug Trial Radar · NCT01001377
ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
Last checked: Nov 20, 2026Latest source record: Sep 21, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,010
Actual
Start
Feb 2, 2010
Primary completion
Feb 5, 2013
Study completion Mar 7, 2017
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- First posted
- Oct 26, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to compare the effect of panitumumab versus cetuximab on overall survival (OS) for chemorefractory metastatic colorectal cancer (mCRC) among patients with wild-type Kirsten rat Sarcoma-2 virus (KRAS) tumors.
Conditions
- Metastatic Colorectal Cancer
Interventions
CetuximabDrug
Administered by intravenous infusion
PanitumumabDrug
Administered by intravenous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall SurvivalTime frame: From randomization until the data cut-off date of 5 February 2013. Maximum time on study was 155 weeks.
Locations
152 sites in 29 countries. Site status is shown where the registry gives one.
Research Site
Stockton, California
Research Site
Boynton Beach, Florida
Research Site
Wichita, Kansas
Research Site
Temple, Texas
Research Site
Ogden, Utah
Research Site
Liverpool, New South Wales, Australia
Research Site
St Leonards, New South Wales, Australia
Research Site
Wahroonga, New South Wales, Australia
Research Site
Wollongong, New South Wales, Australia
Research Site
Woodville South, South Australia, Australia
Research Site
Ballarat, Victoria, Australia
Research Site
Box Hill, Victoria, Australia
Research Site
Epping, Victoria, Australia
Research Site
Footscray, Victoria, Australia
Research Site
Heidelberg, Victoria, Australia
Research Site
Parkville, Victoria, Australia
Research Site
Edegem, Belgium
Research Site
Sofia, Bulgaria
Research Site
Sofia, Bulgaria
Research Site
Edmonton, Alberta, Canada
Research Site
Halifax, Nova Scotia, Canada
Research Site
Beijing, China
Research Site
Beijing, China
Research Site
Beijing, China
Research Site
Shanghai, China
Research Site
Shanghai, China
Research Site
Shanghai, China
Research Site
Tianjin, China
Research Site
Guangzhou, Guangdong, China
Research Site
Guangzhou, Guangdong, China
Research Site
Guangzhou, Guangdong, China
Research Site
Guangzhou, Guangdong, China
Research Site
Harbin, Heilongjiang, China
Research Site
Changsha, Hunan, China
Research Site
Nanjing, Jiangsu, China
Research Site
Changchun, Jilin, China
Research Site
Xi'an, Shaanxi, China
Research Site
Shanghai, Shanghai Municipality, China
Research Site
Chengdu, Sichuan, China
Research Site
Chongqing, Sichuan, China
Showing 40 of 152 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.